Our top pick for
UroGen Pharma Ltd is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. UroGen Pharma employs 187 staff and has a trailing 12-month revenue of around USD$3.8 million.
|52-week range||USD$13.1184 - USD$30.89|
|50-day moving average||USD$22.5396|
|200-day moving average||USD$21.5923|
|Wall St. target price||USD$41|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.888|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$3.8 million|
|Gross profit TTM||USD$18,000|
|Return on assets TTM||-45.25%|
|Return on equity TTM||-82.63%|
|Market capitalisation||USD$474.6 million|
TTM: trailing 12 months
There are currently 2.6 million UroGen Pharma shares held short by investors – that's known as UroGen Pharma's "short interest". This figure is 0.9% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting UroGen Pharma shares can be evaluated.
UroGen Pharma's "short interest ratio" (SIR) is the quantity of UroGen Pharma shares currently shorted divided by the average quantity of UroGen Pharma shares traded daily (recently around 202772.34701782). UroGen Pharma's SIR currently stands at 12.91. In other words for every 100,000 UroGen Pharma shares traded daily on the market, roughly 12910 shares are currently held short.
However UroGen Pharma's short interest can also be evaluated against the total number of UroGen Pharma shares, or, against the total number of tradable UroGen Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case UroGen Pharma's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 UroGen Pharma shares in existence, roughly 120 shares are currently held short) or 0.1471% of the tradable shares (for every 100,000 tradable UroGen Pharma shares, roughly 147 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against UroGen Pharma.
Find out more about how you can short UroGen Pharma stock.
We're not expecting UroGen Pharma to pay a dividend over the next 12 months.
Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $13.1184 up to $30.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.2555. This would suggest that UroGen Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.